PDCD1 and esophageal squamous cell carcinoma: The clinical trial CheckMate-648 has proved that ipilimumab (anti-CTLA-4) combined with nivolumab (anti-PD-1) in first-line treatment could improve overall survival (OS) with durable objective responses and acceptable safety compared to chemotherapy alone for ESCC patients (25).